Individualized Molecular Profiling for Allocation to Clinical Trials (IMPACT) Project (IMPACT)

This study is currently recruiting participants.

See

Contacts and Locations

Verified June 2016 by National Cancer Centre, Singapore

Sponsor:

Information provided by (Responsible Party):

National Cancer Centre, Singapore

ClinicalTrials.gov Identifier:

NCT02806388

First received: June 16, 2016

Last updated: June 17, 2016

Last verified: June 2016

History of Changes

Purpose

This study aims to screen tumor molecular profile for better selection of anticancer treatment, in particular, allocation to clinical trials if available.

Condition
Solid Tumor


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Retrospective
Official Title:	Individualized Molecular Profiling for Allocation to Clinical Trials (IMPACT) Project

Further study details as provided by National Cancer Centre, Singapore:

Primary Outcome Measures:

The molecular and clinical epidemiology for cancer patients being considered for novel therapeutics [ Time Frame: 5 years ]

Secondary Outcome Measures:

The proportion of patients who have actionable alterations and enrol into clinical trials [ Time Frame: 5 years ]
The correlation of molecular profiles with clinical outcomes [ Time Frame: 5 years ]

Biospecimen Retention: Samples With DNA

Remaining tumor and/or blood and/or saliva


Estimated Enrollment:	1500
Study Start Date:	October 2011
Estimated Study Completion Date:	December 2018
Estimated Primary Completion Date:	December 2018 (Final data collection date for primary outcome measure)

Groups/Cohorts
tumor tissue for molecular profiling

Detailed Description:

Molecular profiling will be performed on archival tumor tissue or freshly collected tumor tissue from re-biopsy. Blood and/or saliva may be collected to study the genetic makeup and also to compare the tumor molecular profile. Personalized therapy will be given based on molecular profile.

Eligibility


Ages Eligible for Study:	21 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Any advanced cancer patient who would benefit from molecular profiling and is a potential clinical trial candidate as identified by treating physician.

Criteria

Inclusion Criteria:

Confirmed histological diagnosis of solid tumor
Suitable for systematic treatment and clinical trials
ECOG (Eastern cooperative oncology group) performance status < 2
Able to provide tumor tissue for molecular profiling
Able to understand and sign the informed consent form

Exclusion Criteria:

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02806388

Contacts


Contact: Lanying wang	65-64368267	nctwly@nccs.com.sg

Locations


Singapore
National Cancer Centre singapore	Recruiting
Singapore, Singapore
Contact: Lanying Wang 64368267

Sponsors and Collaborators

National Cancer Centre, Singapore

Investigators


Principal Investigator:	Daniel SW Tan	National Cancer Centre, Singapore

More Information


Responsible Party:	National Cancer Centre, Singapore
ClinicalTrials.gov Identifier:	NCT02806388 History of Changes
Other Study ID Numbers:	ECRU-IMPACT
Study First Received:	June 16, 2016
Last Updated:	June 17, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

ClinicalTrials.gov processed this record on July 17, 2017

To Top